Opioid Dependence Treatment Market Analysis

Drug Cases (Naloxone, Buprenorphine, Methadone)

The global opioid dependence treatment market is segmented and analyzed for demand and supply by drug cases into naloxone, buprenorphine, and methadone. Out of these, the buprenorphine segment is anticipated to hold the largest market share by the end of 2037. This can be attributed to the high demand for these drugs in the developed market such as the US and France. In the United States, buprenorphine is approved by the Food and Drug Administration (FDA) for the treatment of opioid addiction. In 2019, more than 1.3 million buprenorphine prescriptions were issued in the United States. Moreover, the buprenorphine segment has grown in recent years as more healthcare providers recognize the benefits of MAT or medication-assisted treatment of opioid addiction.

Sales Channel (Retail Pharmacies, Online Pharmacies, Hospitals, Rehabilitation Centers)

The global opioid dependence treatment market is segmented and analyzed for demand and supply by sales channel into retail pharmacies, online pharmacies, hospitals, and rehabilitation centers. Out of these, the hospital segment is anticipated to hold the largest market share by the end of 2037. Treatment for opioid dependence is often given in hospitals, especially for individuals who need inpatient treatment or detoxification. Hospitals can also provide outpatient care and aftercare services to people who have completed inpatient care. This is expected to drive the growth of this segment in the forecast period.

Our in-depth analysis of the global market includes the following segments: